Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increasing use of genetic testing raises questions about disclosing secondary findings, including pleiotropic information. OBJECTIVE: To determine the safety and behavioral effect of disclosing modest associations between apolipoprotein E (APOE) genotype and coronary artery disease (CAD) risk during APOE-based genetic risk assessments for Alzheimer disease (AD). DESIGN: Randomized, multicenter equivalence clinical trial. (ClinicalTrials.gov: NCT00462917). SETTING: 4 teaching hospitals. PARTICIPANTS: 257 asymptomatic adults were enrolled, 69% of whom had 1 AD-affected first-degree relative. INTERVENTION: Disclosure of genetic risk information about AD and CAD (AD+CAD) or AD only (AD-only). MEASUREMENTS: Primary outcomes were Beck Anxiety Inventory (BAI) and Center for Epidemiologic Studies Depression Scale (CES-D) scores at 12 months. Secondary outcomes were all measures at 6 weeks and 6 months and test-related distress and health behavior changes at 12 months. RESULTS: At 12 months, mean BAI scores were 3.5 in both the AD-only and AD+CAD groups (difference, 0.0 [95% CI, -1.0 to 1.0]), and mean CES-D scores were 6.4 and 7.1 in the AD-only and AD+CAD groups, respectively (difference, 0.7 [CI, -1.0 to 2.4]). Both confidence bounds fell within the equivalence margin of ±5 points. Among carriers of the APOE ε4 allele, distress was lower in the AD+CAD groups (difference, -4.8 [CI, -8.6 to -1.0]) (P = 0.031 for the interaction between group and APOE genotype). Participants in the AD+CAD groups also reported more health behavior changes, regardless of APOE genotype. LIMITATIONS: Outcomes were self-reported by volunteers without severe anxiety, severe depression, or cognitive problems. Analyses omitted 33 randomly assigned participants. CONCLUSION: Disclosure of pleiotropic information did not increase anxiety or depression and may have decreased distress among persons at increased risk for 2 conditions. Providing risk modification information about CAD improved health behaviors. Findings highlight the potential benefits of disclosure of secondary genetic findings when options exist for decreasing risk. PRIMARY FUNDING SOURCE: National Human Genome Research Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orne, M. T. (1962) · American Psychologist · doi:10.1037/h0043424 · Cited by 4,041 · cited 1×
“Self-reported outcomes, particularly those measuring health behaviors, are subject to bias due to participants responding in ways they believe investigators want them to (43).”
Molecular Findings Among Patients Referred for Clinical Whole-Exome Sequencing
Yang, Y., Muzny, D. M., Xia, F., Niu, Z., Person, R., Ding, Y., Ward, P., Braxton, A., Wang, M., Buhay, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.14601 · Cited by 1,360
Trials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032 · cited 1×
“05/2) to account for multiple testing across 2 primary outcomes (40, 41).”
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Understanding Equivalence and Noninferiority Testing
Walker, E., & Nowacki, A. S. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1513-8 · Cited by 751 · cited 1×
“05/2) to account for multiple testing across 2 primary outcomes (40, 41).”
Sample sizes for clinical trials with normal data.
Julious, S. A. (2004) · Statistics in Medicine · doi:10.1002/sim.1783 · Cited by 605
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528 · cited 1×
“The 4 allele of the apolipoprotein E (APOE) gene, which is present in more than 20% of most populations (20), is robustly associated with risk for Alzheimer disease (AD) (21) and has a weaker and less well-known association with risk for coronary artery disease (CAD) (22, 23).”
Cited by
Frieser, M. J., Wilson, S., & Vrieze, S. (2018) · Health Psychology · doi:10.1037/hea0000683 · Cited by 67
Braakhuis, A., Monnard, C. R., Ellis, A., & Rozga, M. (2021) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2020.04.002 · Cited by 29
Ellis, A., Rozga, M., Braakhuis, A., Monnard, C. R., Robinson, K., Sinley, R., Wanner, A., & Vargas, A. J. (2021) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2020.02.009 · Cited by 27
Metadata
- Authors
- Christensen, K. D., Roberts, J. S., Whitehouse, P. J., Royal, C. D. M., Obisesan, T. O., Cupples, L. A., Vernarelli, J. A., Bhatt, D. L., Linnenbringer, E., Butson, M. B., Fasaye, G.-A., Uhlmann, W. R., Hiraki, S., Wang, N., Cook-Deegan, R., Green, R. C., & for the REVEAL Study Group*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-02-02
- Volume
- 164
- Issue
- 3
- Pages
- 155-163
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2265123407
- Cited by
- 45
- References
- 7
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.